Long-term treatment with Takhzyro (lanadelumab) was associated with quality of life gains among people with hereditary angioedema (HAE)…
Articles by Lindsey Shapiro, PhD
Astria Therapeutics intends to move directly into a pivotal trial to support STAR-0215’s regulatory approval for hereditary angioedema…
Garadacimab, a preventive treatment candidate from CSL Behring, led to significant and clinically meaningful reductions in swelling attacks in…
The U.S. Food and Drug Administration (FDA) has extended the approval of Takhzyro (lanadelumab) to include children with…
Rates of prescriptions for Firazyr (icatibant), an on-demand treatment to control swelling episodes in people with hereditary angioedema…
A single injection of STAR-0215, an experimental treatment to prevent swelling attacks in people with hereditary angioedema (HAE), safely…
A single dose of the extended-release formulation of PHA121 — an investigational molecule under development for the prevention and…
A single infusion of the investigational gene therapy NTLA-2002 was well tolerated at two different doses and reduced the number…
Off-label prescription of certain medications indicated for hereditary angioedema (HAE) with C1 deficiency to people with other types of…
A class of medications used to treat diabetes is associated with the occurrence of angioedema, particularly among older adults,…